Celgene Corp (CELG) 91.96 $CELG
Final Glance: Biotechnology companies
AP - Thu Sep 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Celgene Falls 2.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 11, 3:38PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $90.90 to a high of $93.95. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $92.52 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.26% Loss
Comtex SmarTrend(R) - Thu Sep 11, 3:38PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $90.90 to a high of $93.95. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $92.52 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains
at Investor's Business Daily - Thu Sep 11, 3:17PM CDT
The stock market fought back from session lows, closing mostly higher Thursday. The Nasdaq had been down as much as 0.6% in morning trading, but found support around 4560 twice during the session. It closed with a 0.1% gain. The S&P 500 also added...
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Midday Glance: Biotechnology companies
AP - Thu Sep 11, 1:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 11, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CBS, IMPV, TM, CELG and NWSA.
Why Celgene's Stock is up 11% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 11, 7:45AM CDT
Source: Celgene Corporation Celgene's stock price has climbed 11% in 2014. That's good enough to outpace the S&P 500, which has returned just shy of 10%, but not good enough to outperform Celgene's Nasdaq biotechnology index peers, which...
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
How Bad Is This News for Celgene Corporation?
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 09, 12:45PM CDT
When it comes to approving new drugs, the U.K. has some of the globe's toughest price negotiators. The National Institute for Health and Care Excellence, or NICE, has been anything but kind to drugmakers hoping to roll out high-priced medicine in...
Shares of CELG Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 9:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 25.85% as of today's recent price of $93.05.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Final Glance: Biotechnology companies
AP - Thu Sep 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Celgene Falls 2.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 11, 3:38PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $90.90 to a high of $93.95. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $92.52 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Celgene After 2.26% Loss
Comtex SmarTrend(R) - Thu Sep 11, 3:38PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $90.90 to a high of $93.95. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $92.52 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains
at Investor's Business Daily - Thu Sep 11, 3:17PM CDT
The stock market fought back from session lows, closing mostly higher Thursday. The Nasdaq had been down as much as 0.6% in morning trading, but found support around 4560 twice during the session. It closed with a 0.1% gain. The S&P 500 also added...
Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...
Midday Glance: Biotechnology companies
AP - Thu Sep 11, 1:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 11, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver
PR Newswire - Thu Sep 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CBS, IMPV, TM, CELG and NWSA.
Why Celgene's Stock is up 11% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 11, 7:45AM CDT
Source: Celgene Corporation Celgene's stock price has climbed 11% in 2014. That's good enough to outpace the S&P 500, which has returned just shy of 10%, but not good enough to outperform Celgene's Nasdaq biotechnology index peers, which...
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
How Bad Is This News for Celgene Corporation?
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 09, 12:45PM CDT
When it comes to approving new drugs, the U.K. has some of the globe's toughest price negotiators. The National Institute for Health and Care Excellence, or NICE, has been anything but kind to drugmakers hoping to roll out high-priced medicine in...
Shares of CELG Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 9:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 25.85% as of today's recent price of $93.05.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
